1 hour agoBusiness
30LENS
2 SourcesMumbai, India
thebalanced.newsSuven Life Sciences Reports Rs 45.6 Crore Q4 Loss, FY26 Net Loss Widens
Suven Life Sciences reported a consolidated net loss of Rs 45.6 crore in Q4 FY26, slightly higher than Rs 43.9 crore in the same quarter last year but lower than Rs 101.9 crore in the preceding quarter. Revenue for Q4 was Rs 1.52 crore, up marginally year-on-year. For FY26, the net loss widened to Rs 276.34 crore from Rs 160.75 crore in FY25, amid increased research and development and clinical expenses. Total income rose modestly, but elevated costs impacted profitability.
Political Bias
0%100%0%
Sentiment
38%
AI Analysis
Political bias across 2 sources
● Left 0%● Center 100%● Right 0%
The articles present a primarily financial and operational perspective on Suven Life Sciences without political framing. Coverage focuses on company-reported figures, R&D investments, and expense trends. There is no evident political bias, as the sources emphasize factual reporting of financial results and business activities without partisan commentary or ideological interpretation.
Sentiment — Neutral (38/100)
The overall sentiment is mixed to negative, reflecting the widening net losses and increased expenses despite some revenue growth. The tone is factual and restrained, highlighting financial challenges and ongoing investments in research without sensationalizing. Both articles balance reporting losses with explanations of higher R&D spending, resulting in a nuanced but cautious outlook.
How 2 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.
| Source | Their headline | Bias | Sentiment |
|---|---|---|---|
| businessstandard | Suven Life Sciences reports consolidated net loss of Rs 45.60 crore in the March 2026 quarter | Center | Negative |
| freepressjournal | Suven Life Sciences Q4 Loss Narrows To 45.6 Crore, FY26 Loss Widens Amid Higher R D Spend | Center | Neutral |
Coverage timeline
freepressjournal broke this story on 13 May, 09:04 am. Other outlets followed.
- 1freepressjournal13 May, 09:04 amSuven Life Sciences Q4 Loss Narrows To 45.6 Crore, FY26 Loss Widens Amid Higher R D Spend
- 2businessstandard13 May, 10:13 amSuven Life Sciences reports consolidated net loss of Rs 45.60 crore in the March 2026 quarter
Lens Score breakdown
30/100
Public interest0/100
Coverage gap100%
Well-covered story — coverage matches public importance.
Who's involved
Institutions and figures named across source coverage.
Corporate
Suven Life Sciences
Story context
- Category
- Business
- Location
- Mumbai, India
- Sources analysed
- 2
- Last analysed
- 13 May 2026
- Key entities
- CroreIndian rupeeKirloskar BrothersNet incomeIndiaResearch and developmentBiopharmaceuticalRevenueMumbaiDepreciationFiscal yearCommon stock
Related Coverage
Select a news story to see related coverage from other media outlets.